tailieunhanh - Báo cáo y học: "Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist’s role"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist’s role. | Available online http content 8 5 219 Review Bisphosphonate-associated osteonecrosis of the jaw the rheumatologist s role Franco Capsoni1 Matteo Longhi1 and Roberto Weinstein2 1 Rheumatology Unit Istituto Ortopedico Galeazzi IRCCS University of Milan Italy 2Department of Odontology Istituto Ortopedico Galeazzi IRCCS University of Milan Italy Corresponding author Franco Capsoni Published 9 October 2006 This article is online at http content 8 5 219 2006 BioMed Central Ltd Arthritis Research Therapy 2006 8 219 doi ar2050 Abstract Several recent reports have described osteonecrosis of the jaws ONJ associated with the use of bisphosphonates. Rheumatologists treating bone diseases with bisphosphonate need therefore to be aware of this potential risk and plan the prophylaxis early diagnosis and prevention of potential consequences. We review the literature on this newly described complication with particular focus on systemic and local predisposing pathologies preventive measures suggested before and during therapy with bisphosphonates and the most frequent clinical presentation of the oral lesions. The expert panel recommendations for the management of care of patients who develop ONJ are summarized. Introduction Bisphosphonates are becoming increasingly important in the treatment of metabolic and oncological diseases involving the skeleton 1-3 . These carbon-substituted pyrophosphate analogs are potent inhibitors of osteoclast-mediated bone resorption. The most recent nitrogen-containing bisphosphonates or aminobisphosphonates have greater potency and better selectivity the most commonly used aminobisphosphonates include alendronate risedronate ibandronate pamidronate and zoledronate. Alendronate risedronate and ibandronate are used for the prevention and treatment of osteoporosis while pamidronate and zoledronate have an essential role in the prevention of bone complications and the .